2022, ' SARS-CoV-2-specific nasal IgA wanes 9 months after hospitalisation with COVID-19 and is not induced by subsequent vaccination ', EBioMedicine, pp. 104402 . https://doi.org/10.1016/j.ebiom.2022.104402 Liew, F, Talwar, S, Cross, A, Willett, B J, Scott, S, Logan, N, Siggins, M K, Swieboda, D, Sidhu, J K, Efstathiou, C, Moore, S C, Davis, C, Mohamed, N, Nunag, J, King, C, Thompson, A A R, Rowland-Jones, S L, Docherty, A B, Chalmers, J D, Ho, L-P, Horsley, A, Raman, B, Poinasamy, K, Marks, M, Kon, O M, Howard, L, Wootton, D G, Dunachie, S, Quint, J K, Evans, R A, Wain, L V, Fontanella, S, de Silva, T I, Ho, A, Harrison, E, Baillie, J K, Semple, M G, Brightling, C, Thwaites, R S, Turtle, L, Openshaw, P J M, ISARIC4C Investigators, Armour, C, Carson, G, Busby, J, Connolly, B, Cooper, J, Drain, S, Grieve, D, Hart, N, Harvey, M, Heaney, L G, Hughes, J, Jones, M G, Magee, N, McArdle, A, McGarvey, L, Mills, C, Mitchell, J, Peto, T, Powell, N, Rowland, M, Sharma, M & Siddiqui, S 2023, ' SARS-CoV-2-specific nasal IgA wanes 9 months after hospitalisation with COVID-19 and is not induced by subsequent vaccination ', EBioMedicine, vol. 87, 104402 . https://doi.org/10.1016/j.ebiom.2022.104402 Horsley, A, Dark, P, Felton, T, et al, ISARIC4C Investigators & PHOSP-COVID Collaborative Group 2023, ' SARS-CoV-2-specific nasal IgA wanes 9 months after hospitalisation with COVID-19 and is not induced by subsequent vaccination ', EBioMedicine, vol. 87, 104402 . https://doi.org/10.1016/j.ebiom.2022.104402
Mumford, A D & Gibbison, B J J 2022, ' Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY) : a randomised, controlled, open-label, platform trial and updated meta-analysis ', Lancet, vol. 400, no. 10349, pp. 359-368 . https://doi.org/10.1016/S0140-6736(22)01109-6 Dimitriadis, G K 2022, ' Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY) : a randomised, controlled, open-label, platform trial and updated meta-analysis ', Lancet, vol. 400, no. 10349, pp. 359-368 . https://doi.org/10.1016/S0140-6736(22)01109-6 RECOVERY Collaborative Group & Dark, P 2022, ' Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis ', Lancet . https://doi.org/10.1016/S0140-6736(22)01109-6
Lancet (London, England) LANCET RECOVERY Collaborative Group 2021, ' Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY) a randomised controlled, open-label, platform trial ', The Lancet, vol. 397, no. 10289, pp. 2049-2059 . https://doi.org/10.1016/S0140-6736(21)00897-7 Mumford, A D 2021, ' Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY) : a randomised controlled, open-label, platform trial ', Lancet, vol. 397, no. 10289, pp. 2049-2059 . https://doi.org/10.1016/S0140-6736(21)00897-7 Group, RECOVERY C & Dark, P 2021, ' Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial. ', Lancet (London, England), vol. 397, no. 10289, pp. 2049-2059 . https://doi.org/10.1016/S0140-6736(21)00897-7
Relph, K A, Russell, C D, Fairfield, C J, Turtle, L, De Silva, T, Siggins, M K, Drake, T M, Thwaites, R S, Abrams, S, Moore, S C, Hardwick, H E, Oosthuyzen, W, Harrison, E M, Docherty, A B, Openshaw, P J M, Baillie, J K & Semple, M G & Ho, A 2022, ' Procalcitonin Is Not a Reliable Biomarker of Bacterial Coinfection in People With Coronavirus Disease 2019 Undergoing Microbiological Investigation at the Time of Hospital Admission ', Open forum infectious diseases, vol. 9, no. 5 . https://doi.org/10.1093/ofid/ofac179 Investigators, I S A R A E I C C C C C ISARICC & Dark, P 2022, ' Procalcitonin Is Not a Reliable Biomarker of Bacterial Coinfection in People With Coronavirus Disease 2019 Undergoing Microbiological Investigation at the Time of Hospital Admission. ', Open Forum Infectious Diseases, vol. 9, no. 5, ofac179 . https://doi.org/10.1093/ofid/ofac179
RECOVERY Collaborative Group & Downey, D 2022, ' Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial ', The Lancet, vol. 399, no. 10325, pp. 665-676 . https://doi.org/10.1016/S0140-6736(22)00163-5 Mumford, A D 2022, ' Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY) : a randomised, controlled, open-label, platform trial ', Lancet, vol. 399, no. 10325, pp. 665-676 . https://doi.org/10.1016/S0140-6736(22)00163-5 Lancet (London, England) Group, RECOVERY C, Felton, T, Dark, P & Mathioudakis, A 2022, ' Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial ', Lancet (London, England), vol. 399, no. 10325, pp. 665-676 . https://doi.org/10.1016/S0140-6736(22)00163-5
Nephrology Dialysis Transplantation Investigators, ISARICC & Dark, P 2022, ' Acute kidney injury in patients hospitalized with COVID-19 from the ISARIC WHO CCP-UK Study: a prospective, multicentre cohort study. ', Nephrology, dialysis, transplantation, vol. 37, no. 2, pp. 271-284 . https://doi.org/10.1093/ndt/gfab303 Sullivan, M K, Lees, J S, Docherty, A B, Oates, G, Hardwick, H E, Russell, C D, Merson, L, Dunning, J, Nguyen-Van-Tam, J S, Openshaw, P, Harrison, E M, Baillie, J K, Investigators, ISARICC, Semple, M G, Ho, A & Mark, P B 2021, ' Acute kidney injury in patients hospitalised with COVID-19 from the ISARIC WHO CCP-UK Study: a prospective, multicentre cohort study ', PLoS Medicine . https://doi.org/10.1093/ndt/gfab303